Focused Solutions for Oncology
Pieris Pharmaceuticals is proud to partner with industry leaders in immuno-oncology. Read how these key partnerships are helping us produce superior outcomes for patients.
Immuno-Oncology
Candidate
Targets
Partner
Discovery
Preclinical
Phase 1
Phase 2
Candidate
PRS-346/SGN-BB228
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
PRS-342/BOS-342
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
Candidate Seagen Programs‡
Partner
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
‡ 2 active bispecific programs in collaboration with Pfizer in addition to PRS-346/SGN-BB228 listed above.